Dr Cheney Drew

2021

• Woodgate, S.et al. 2021. Objectively characterizing Huntington’s disease using a novel upper limb dexterity test. Journal of Neurology 268, pp. 2550-2559. (10.1007/s00415-020-10375-8)
• Drew, C.et al. 2021. Protocol for an open label, phase I trial within a cohort of fetal cell transplants in people with Huntington’s disease. Brain Communications 3(1), article number: fcaa230. (10.1093/braincomms/fcaa230)

2020

• Sanders, J.et al. 2020. Pregnancy and weight monitoring: a feasibility study of weightcharts and midwife support. Maternal and Child Nutrition 16(4), article number: e12996. (10.1111/mcn.12996)
• Yhnell, E.et al. 2020. A randomised feasibility study of computerised cognitive training as a therapeutic intervention for people with Huntington's disease (CogTrainHD). Pilot and Feasibility Studies 6, article number: 88. (10.1186/s40814-020-00623-z)

2019

• Drew, C. J. G.et al. 2019. Physical activity and exercise outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month trial within cohort evaluation of a physical activity intervention in people with Huntington Disease. Physical Therapy 99(9), pp. 1201-1210. (10.1093/ptj/pzz075)
• Drew, C. J. G.et al. 2019. A protocol for a randomised controlled, double-blind feasibility trial investigating fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, Learning and Memory in Epilepsy (FLAME trial). Pilot and Feasibility Studies 5(1), article number: 87. (10.1186/s40814-019-0474-x)
• Morgan-Trimmer, S.et al. 2019. The acceptability of fluoride varnish and fissure sealant treatments in children aged 6-9 delivered in a school setting. Community Dental Health 36(1), pp. 33-38. (10.1922/CDH_4263Morgan-Trimmer06)

2017

• Chestnutt, I. G.et al. 2017. Fissure seal or fluoride varnish? A randomised trial of their relative effectiveness. Journal of Dental Research 96(7), pp. 754-761. (10.1177/0022034517702094)
• Busse, M.et al. 2017. Physical activity self-management and coaching compared to social interaction in Huntington’s disease: Results from the ENGAGE-HD randomized, controlled, pilot feasibility trial. Physical Therapy 97(6), pp. 625-639. (10.1093/ptj/pzx031)
• Chestnutt, I. G.et al. 2017. Seal or Varnish? A randomised controlled trial to determine the relative cost and effectiveness of pit and fissure sealant and fluoride varnish in preventing dental decay. Health Technology Assessment 21(21), pp. 1-256. (10.3310/hta21210)

2016

• Drew, C.et al. 2016. Integrating technology into complex intervention trial processes: a case study. Trials 17(1), article number: 551. (10.1186/s13063-016-1674-9)
• Jones, C.et al. 2016. The societal cost of Huntington’s disease: are we underestimating the burden?. European Journal of Neurology 23(10), pp. 1588-1590. (10.1111/ene.13107)
• Randell, E.et al. 2016. The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. Trials 17, article number: 398. (10.1186/s13063-016-1446-6)
• Fry, A. E.et al. 2016. Pathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy. BMC Medical Genetics 17, pp. -., article number: 34. (10.1186/s12881-016-0294-2)
• Quinn, L.et al. 2016. Development and delivery of a physical activity intervention for people with Huntington Disease. Journal of Neurologic Physical Therapy 40(2), pp. 71-80. (10.1097/NPT.0000000000000119)

2015

• Thomas, R. H.et al. 2015. Ethnicity can predict GLRA1 genotypes in hyperekplexia. Journal of Neurology, Neurosurgery & Psychiatry 86(3), pp. 341-343. (10.1136/jnnp-2014-307903)

2012

• Thompson, R., Drew, C. and Thomas, R. H. 2012. Next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges. Advances in Protein Chemistry and Structural Biology 89, pp. 27-63. (10.1016/B978-0-12-394287-6.00002-1)